You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

BENICAR HCT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Benicar Hct patents expire, and when can generic versions of Benicar Hct launch?

Benicar Hct is a drug marketed by Cosette and is included in one NDA.

The generic ingredient in BENICAR HCT is hydrochlorothiazide; olmesartan medoxomil. There are thirty-two drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; olmesartan medoxomil profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for BENICAR HCT?
  • What are the global sales for BENICAR HCT?
  • What is Average Wholesale Price for BENICAR HCT?
Drug patent expirations by year for BENICAR HCT
Drug Prices for BENICAR HCT

See drug prices for BENICAR HCT

Drug Sales Revenue Trends for BENICAR HCT

See drug sales revenues for BENICAR HCT

Recent Clinical Trials for BENICAR HCT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
EMSPhase 3
Daiichi Sankyo Co., Ltd.N/A
Chinese PLA General HospitalPhase 4

See all BENICAR HCT clinical trials

Pharmacology for BENICAR HCT
Paragraph IV (Patent) Challenges for BENICAR HCT
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
BENICAR HCT Tablets hydrochlorothiazide; olmesartan medoxomil 20 mg/12.5 mg 021532 1 2007-05-11
BENICAR HCT Tablets hydrochlorothiazide; olmesartan medoxomil 40 mg/12.5 mg and 40 mg/25 mg 021532 1 2007-02-15

US Patents and Regulatory Information for BENICAR HCT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cosette BENICAR HCT hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 021532-002 Jun 5, 2003 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Cosette BENICAR HCT hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 021532-003 Jun 5, 2003 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Cosette BENICAR HCT hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 021532-005 Jun 5, 2003 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BENICAR HCT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cosette BENICAR HCT hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 021532-003 Jun 5, 2003 ⤷  Sign Up ⤷  Sign Up
Cosette BENICAR HCT hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 021532-002 Jun 5, 2003 ⤷  Sign Up ⤷  Sign Up
Cosette BENICAR HCT hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 021532-005 Jun 5, 2003 ⤷  Sign Up ⤷  Sign Up
Cosette BENICAR HCT hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 021532-003 Jun 5, 2003 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for BENICAR HCT

See the table below for patents covering BENICAR HCT around the world.

Country Patent Number Title Estimated Expiration
Norway 954507 ⤷  Sign Up
Japan 2003048852 MEDICAL COMPOSITION ⤷  Sign Up
Hungary 223667 1-Bifenil-metil-imidazol-származékok, eljárás ezek előállítására és ilyen vegyületeket tartalmazó gyógyászati készítmények (1-BIPHENYL-METHYL-IMIDAZOL DERIVATIVES, PROCESS FOR PRODUCING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM) ⤷  Sign Up
Austria 324890 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for BENICAR HCT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0565634 06C0030 France ⤷  Sign Up PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
0503785 CA 2009 00015 Denmark ⤷  Sign Up PRODUCT NAME: EN KOMBINATION AF OLMESARTANMEDOXOMIL, EVT. I FORM AF ET FARMACEUTISK ACCEPTABELT SALT OG AMLODIPIN-BESILAT; NAT. REG. NO/DATE: MT 42061, 42062, 42063 20081120; FIRST REG. NO/DATE: NL RVG 100984 20080819
0503785 C00503785/03 Switzerland ⤷  Sign Up FORMER REPRESENTATIVE: BOHEST AG, CH
0503785 91056 Luxembourg ⤷  Sign Up 91056, EXPIRES: 20170221
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.